Read review Dihexa for Sleep Apnea Brain Fog OSA & hypoxemia, REM CA1 hippocampal loss (UC Irvine May 2025), Zepbound (tirzepatide) FDA approval Dec 2024 (SURMOUNT-OSA), NICE NG202, and the ~13 million UK adults estimated to have OSA
Oral formulations are mainly discussed for gastrointestinal applications, but research remains limited
Inflammation and injury to the joint cause changes in bone-joint structure, deterioration of tendons and ligaments, and a breakdown of cartilage
New challenges in vascular biology and medicine: from unravelling the mechanisms of neointima formation to the prevention of amputations and of ischaemic stroke
However, important limitations remain
With regular maintenance, the benefits may last several months or more